Vigil Neuroscience, Inc. (VIGL)

3,0300 +0,2900 (+10,58%) Alla chiusura: 04:00PM EDT

Vigil Neuroscience, Inc.

100 Forge Road
Suite 700 Watertown
Watertown, MA 02472
United States
857 254 4445
https://www.vigilneuro.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 69

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.	President, CEO & Director	903,86k	N/D	1967
Ms. Jennifer Ziolkowski CPA	Chief Financial Officer	629,08k	N/D	1975
Ms. Leah Gibson	Vice President of Investor Relations and Corporate Communications	N/D	N/D	N/D
Mr. Christopher Verni J.D.	General Counsel & Corporate Secretary	N/D	N/D	1975
April Effort M.B.A., M.S.	VP & Head of Corporate Development	N/D	N/D	N/D
Mr. Evan A. Thackaberry DABT, Ph.D.	Senior VP & Head of Early Development	N/D	N/D	1973
Christian Mirescu Ph.D.	VP & Head of Neuroimmunology	N/D	N/D	N/D
Weeteck Yeo Ph.D.	Senior Vice President of Strategic Operations	N/D	N/D	N/D
Andreas Meier M.D.	Senior Vice President of Clinical & Medical Sciences	N/D	N/D	N/D
Jessica Stromme P.M.P.	Senior Vice President of Program Leadership & Portfolio Management	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Vigil Neuroscience, Inc. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 4; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.